 |
      |
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
Glaucoma is a group of diseases that can damage the eye's optic nerve and result in vision loss and blindness. Approximately 2.2 million Americans have been diagnosed with glaucoma.1 It is typically characterized by elevated pressure inside the eye, otherwise known as intraocular pressure, or IOP. While glaucoma is a lifelong condition, lowering IOP with daily treatment can prevent further |
 |
|
Indication: ALPHAGAN® P 0.1% ophthalmic solution is approved for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Important Safety Information Contraindication: ALPHAGAN® P 0.1% is contraindicated in patients receiving monoamine oxidase (MAO) inhibitor therapy. Precautions: Although ALPHAGAN® P 0.1% ophthalmic solution had minimal effect on the blood pressure of patients in clinical studies, caution should be exercised in treating patients with severe cardiovascular disease. ALPHAGAN® P 0.1% should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, or thromboangiitis obliterans. Adverse reactions: Adverse events occurring in approximately 10% to 20% of the subjects included: allergic conjunctivitis, conjunctival hyperemia, and eye pruritus. Adverse events occurring in approximately 5% to 9% included: burning sensation, conjunctival folliculosis, hypertension, ocular allergic reaction, oral dryness, and visual disturbance. Please click here for full product information. 1. More Americans facing blindness than ever before [press release]. National Eye Institute Web site. http://www.nei.nih.gov/news/pressreleases/032002.asp. Accessed August 12, 2009. |
|
©2009 Allergan, Inc., Irvine, CA 92612 | ® marks owned by Allergan, Inc. |